GlassScriptPhysician profile
Madison G Abrams
NPI 1609495571
$2,228.74
in general payments reported to CMS, 2019-2025
33 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $230 · 2023: $561 · 2024: $750 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291.76 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $277.98 | 2021-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $208.72 | 2023-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $143.82 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $130.70 | 2023-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.43 | 2021-2024 | Cyltezo, Ofev |
| Lilly USA, LLC | $108.65 | 2022-2024 | Taltz, Zepbound |
| Radius Health, INC. | $106.40 | 2024-2025 | Tymlos |
| Glaxosmithkline, LLC. | $97.62 | 2021-2025 | Benlysta |
| Pfizer INC. | $92.73 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $57.39 | 2024-2025 | Opsumit |
| Collegium Pharmaceutical, INC. | $50.93 | 2025 | Belbuca |
| Organon LLC | $50.56 | 2023-2024 | Hadlima |
| Boston Scientific Corporation | $50.29 | 2022-2025 | Intracept |
| Genzyme Corporation | $47.33 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $45.13 | 2025 | Pemgarda |
| Bioventus LLC | $32.88 | 2025 | Durolane |
| Almatica Pharma LLC | $28.39 | 2024 | Loreev Xr |
| Genentech USA, INC. | $27.83 | 2023-2025 | Actemra, Rituxan |
| Teva Pharmaceuticals USA, INC. | $26.39 | 2025 | Ajovy |
| Sandoz INC. | $25.44 | 2024 | Hyrimoz |
| Protega Pharmaceutials INC | $23.54 | 2025 | Roxybond |
| Celltrion USA INC. | $21.82 | 2024 | Vegzelma |
| Averitas Pharma INC. | $18.24 | 2025 | Qutenza |
| Shorla Oncology INC. | $18.21 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.75 | 2024 | Arcalyst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2025 | Relistor |
| Biogen, INC. | $16.15 | 2024 | Tofidence |
| Fresenius Kabi USA, LLC | $15.88 | 2023 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $15.85 | 2024 | Orencia |
| Ani Pharmaceuticals, INC. | $14.43 | 2024 | Purified Cortrophin Gel |
| Tersera Therapeutics LLC | $13.94 | 2025 | Quzyttir |
| Medtronic, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.